A Penny Saved: Why Delaying 340B Pricing Rule Is Good News For Companies Like Horizon
HRSA proposes another delay to effective date of final rule on calculating the ceiling prices for drugs sold to 340B program. Agency also appears ready to reconsider the 'penny pricing' policy that rule would codify.
You may also be interested in...
Leaders of key health care committees urge HRSA to move ahead quickly with regulations, which might mean implementing a 2017 final rule or issuing a new proposed rule.
Proposed rule will revisit controversial provisions in the January 340B final rule to address manufacturer concerns about the US discount program.
Manufacturers pinpoint flaws in and outline alternatives to HRSA's plan to codify the now non-binding policy of charging a penny per pill for certain products. Concerns are raised about stockpiling and drug diversion, in addition to fair payment.